Improving transplantation outcomes
Hypothermic machine perfusion (HMP) is increasingly becoming standard of care when preserving and transporting kidneys for transplantation. Studies have demonstrated that standard HMP:
Significantly reduces the risk of delayed graft function, DGF, compared to static cold storage (SCS). This is true for both DBD and DCD kidneys [1].
Kidney Assist Transport leverages the clinical outcomes of standard HMP with the added benefits of continuous oxygenation, so called HOPE. The results from a multicenter, double-blinded, randomized controlled trial, comprising 106 donor pairs from DCD donors age ≥50, showed that recipients of HOPE treated kidneys at 1 year folllow-up experienced [2]:
11.7%
Improved renal function
44%
Lowered incidence of acute rejection
31%
Reduced incidence of severe post-transplant complications
